Bicalutamide alone prior to brachytherapy achieves cytoreduction that is similar to luteinizing hormone-releasing hormone analogues with less patient-reported morbidity

Urologic Oncology: Seminars and Original Investigations

Volumn 26, Issue 4, 2008, Pages 372-377

  Petit, Joshua H ^a   Gluck, Clifford ^a   Kiger III, W S ^a   Henry, D Laury ^a   Karasiewicz, Carol ^a   Talcott, James ^b   Berg, Solomon ^a   Holupka, Edward ^a   Kaplan, Irving ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Bicalutamide; Brachytherapy; Prostate cancer; Volume reduction

Indexed keywords

BICALUTAMIDE; GONADORELIN DERIVATIVE; GOSERELIN; LEUPRORELIN;

ADULT; AGED; ANDROGEN THERAPY; ARTICLE; BRACHYTHERAPY; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; EARLY DIAGNOSIS; FOLLOW UP; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; URINE RETENTION;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANILIDES; ANTINEOPLASTIC AGENTS, HORMONAL; BRACHYTHERAPY; COMBINED MODALITY THERAPY; GOSERELIN; HUMANS; LEUPROLIDE; MALE; MIDDLE AGED; MORBIDITY; NITRILES; PROSTATIC NEOPLASMS; TOSYL COMPOUNDS;

EID: 45849106157     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2007.05.014     Document Type: Article

References (29)

1. Prestidge B.R. Radioisotopic implantation for carcinoma of the prostate: Does it work better than it used to?. Semin Radiat Oncol 8 (1998) 124-132
2. Boccardo F., Pace M., Rubagotti A., et al. Goserelin acetate with or without flutamide in the treatment of patients with locally advanced or metastatic prostate cancer. The Italian Prostatic Cancer Project (PONCAP) Study Group. Eur J Cancer 29A (1993) 1088-1093
3. Lamb D.S., Denham J.W., Mameghan H., et al. Acceptability of short term neo-adjuvant androgen deprivation in patients with locally advanced prostate cancer. Radiother Oncol 68 (2003) 255-267
4. Metz R., Namer M., Adenis L., et al. Zoladex as primary therapy in advanced prostatic cancer. A French cooperative trial. Am J Clin Oncol 11 Suppl 2 (1988) 112-S114
5. Negat R.J., Rashid H.H., Bagiella E., et al. A prospective analysis of time to normalization of serum testosterone after withdrawal of androgen deprivation therapy. J Urol 164 (2000) 1891-1894
6. Padula G.D., Zelefsky M.J., Venkatraman E.S., et al. Normalization of serum testosterone levels in patients treated with neoadjuvant hormonal therapy and three-dimensional conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 52 (2002) 439-443
7. Asbell S.O., Leon S.A., Tester W.J., et al. Development of anemia and recovery in prostate cancer patients treated with combined androgen blockade and radiotherapy. Prostate 29 (1996) 243-248
8. Berruti A., Dogliotti L., Terrone C., et al. Changes in bone mineral density, lean body mass, and fat content as measured by dual energy X-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. Urology 167 (2002) 2361-2367
9. Eri L.M., and Tveter K.J. Safety, side effects and patient acceptance of the luteinizing hormone releasing hormone agonist leuprolide in treatment of benign prostatic hyperplasia. J Urol 152 (1994) 448-452
10. Mittan D., Lee S., Miller E., et al. Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endo Met 87 (2002) 3656-3661
11. Rosenblatt D.E., and Mellow A. Depression during hormonal treatment of prostate cancer. J Am Board Fam Pract 8 (1995) 317-320
12. Stone P., Hardy J., Huddart R., et al. Fatigue in patients with prostate cancer receiving hormone therapy. Eur J Canc 36 (2000) 1134-1141
13. Crook J., McLean M., Catton C., et al. Factors influencing risk of acute urinary retention after TRUS-guided permanent prostate seed implantation. Int J Radiat Oncol Biol Phys 52 (2002) 453-460
14. Niehaus A., Merrick G.S., Butler W.M., et al. The influence of isotope and prostate volume on urinary morbidity after prostate brachytherapy. Int J Radiat Oncol Biol Phys 64 (2005) 136-143
15. Terk M.D., Stock R.G., and Stone N.N. Identification of patients at increased risk for prolonged urinary retention following radioactive seed implantation of the prostate. J Urol 160 (1998) 1379-1382
16. Vargas C., Ghilezan M., Hollander M., et al. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy. J Urol 174 (2005) 882-887
17. Keating N., O'Malley J., and Smith M.R. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 24 (2006) 4448-4456
18. Iversen P., Tyrrell C.J., Kaisary A.V., et al. Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: Results from two multicenter randomized trials at a median follow-up of four years. Urology 51 (1998) 389-396
19. Wirth M., Tyrrell C., Wallace M., et al. Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression. Urology 58 (2001) 146-150
20. Eri L.M., and Tveter K.J. A prospective, placebo-controlled study of the antiandrogen Casodex as treatment for patients with benign prostatic hyperplasia. J Urol 150 (1993) 90-94
21. Eri L.M., and Tveter K.J. A prospective, placebo-controlled study of the luteinizing hormone-releasing hormone agonist leuprolide as treatment for patients with benign prostatic hyperplasia. J Urol 150 (1993) 359-364
22. Henderson A., Langley S., and Laing R.W. Is bicalutamide equivalent to goserelin for prostate volume reduction before radiation therapy?. A prospective, observational study. Clin Oncol 15 (2003) 318-321
23. Clark J.A., Rieker P., Propert K.J., et al. Changes in quality of life following treatment for early stage prostate cancer. Urology 53 (1999) 161-168
24. Clark J.A., and Talcott J. Symptom indexes to assess outcomes of treatment for early stage prostate cancer. Medical Care 39 (2001) 1118-1130
25. Kucway R., Vicini F., Huang R., et al. Prostate volume reduction with androgen deprivation before interstitial brachytherapy. J Urol 167 (2002) 2443-2447
26. Whittington R., Broderick G., Arger P., et al. The effect of androgen deprivation on the early changes in prostate volume following transperineal ultrasound guided interstitial therapy for localized carcinoma of the prostate. Int J Radiat Oncol Biol Phys 44 (1999) 1107-1111
27. Narayan P., Trachtenberg J., Lepor H., et al. A dose-response study of the effect of flutamide on benign prostatic hyperplasia: Results of a multicenter study. Urology 47 (1996) 497-504
28. Boccardo F., Rubagotti A., Barichello M., et al. Bicalutamide monotherapy vs. flutamide plus goserelin in prostate cancer patients: Results of an Italian Prostate Cancer Project study. J Clin Oncol 17 (1999) 2027-2038
29. Tyrrell C.J., Blake G.M., Iversen P., et al. The nonsteroidal antiandrogen, bicalutamide (Casodex), may preserve bone mineral density compared with castration: Results of a preliminary study. World J Urol 21 (2003) 37-42